namilumab – Talk Bio

Actionable Insights Powered by AI

Roivant’s Kinevant Discontinues Namilumab Development for Pulmonary Sarcoidosis After Phase 2 Failure

2 months ago talkbio0Tagged Drug Development, Failure (biologic function), Kinevant, namilumab, Phase 2 clinical trial, Roivant, Sarcoidosis, Pulmonary

Roivant Sciences, Kinevant, namilumab, pulmonary sarcoidosis, Phase 2 clinical trial, RESOLVE-Lung study, drug development failure

Roivant Halts Lung Disease Drug Development as Bio-Thera and Intas Forge Biosimilar Partnership

2 months ago talkbio0Tagged Accord BioPharma, Bio-Thera, Biopharma, Biosimilars, golimumab, Intas, namilumab, Roivant, Sarcoidosis, Pulmonary, Solutions

Roivant Sciences, namilumab, pulmonary sarcoidosis, Bio-Thera Solutions, Intas Pharmaceuticals, golimumab biosimilar, BAT2506, Accord BioPharma

Kinevant Sciences Discontinues Namilumab Development for Pulmonary Sarcoidosis Following Phase 2 Failure

5 months ago talkbio0Tagged Anti-GM-CSF, Kinevant, Monoclonal Antibodies, namilumab, Phase 2 Clinical Trials, Sarcoidosis, Pulmonary, Science

Namilumab, Pulmonary Sarcoidosis, Phase 2 Study, Kinevant Sciences, RESOLVE-Lung Study, Anti-GM-CSF Monoclonal Antibody